WASHINGTON, Feb. 5 /PRNewswire-USNewswire/ -- Notice is hereby given that Finkelstein Thompson LLP has filed a Class Action lawsuit in the United State District Court for the Western District of Washington on behalf of a class (the "Class") consisting of all persons or entities who purchased or otherwise acquired the common stock of CellCyte Genetics Corporation ("CellCyte" or the "Company") (OTC Bulletin Board: CCYG.OB) between April 6, 2007 and January 9, 2008 inclusive (the "Class Period").
A copy of the Complaint is available from the court or from Finkelstein Thompson LLP. Please call us toll-free at (877) 337-1050 to discuss this action or to obtain a copy of the Complaint. You may also contact us by email at firstname.lastname@example.org, or visit our website at http://www.finkelsteinthompson.com.
The Complaint alleges that CellCyte misled the investing public throughout the Class Period by publishing false information about the history and experience of the company's chief executive officer Gary A. Reys. Specifically, Plaintiff alleges that CellCyte misrepresented Reys' credentials on the Company's website and in SEC filings, particularly regarding Reys' educational background, his status as a certified public accountant in the state of Washington, and his prior role in the initial public offerings of var2ious pharmaceutical companies.
According to the Complaint, CellCyte made false and misleading statements about Reys to the SEC and potential investors. The truth regarding Reys' credentials began to surface in early January after news media inquiries into Reys' background. Shortly after these inquiries, CellCyte removed numerous claims regarding Reys' credentials from the Company's website.
As a result of Defendant's misrepresentations and omissions, CellCyte's
stock traded at inflated levels during
|SOURCE Finkelstein Thompson LLP|
Copyright©2008 PR Newswire.
All rights reserved